Bar-Or Amit
Experimental Therapeutics Program, Montreal Neurological Institute, Montreal, Quebec, Canada.
Semin Neurol. 2008 Feb;28(1):29-45. doi: 10.1055/s-2007-1019124.
Recent years have witnessed a remarkable growth in literature related to the biology and treatment of multiple sclerosis (MS). The focus of this article is on aspects of the human immune response that have been implicated in the MS disease process and, as a corollary, represent rational targets for the development of safe and effective therapies. Much of the thinking about immune pathophysiology in patients with MS has been shaped by studies in animal models of central nervous system (CNS) inflammation. Translation to the human disease has continued to pose challenges. A simplified model of MS immune pathophysiology is presented to illustrate the basic principles by which peripheral immune activation, as well as compartmentalized immune responses within the CNS, is likely to impact the disease process and to identify the putative sites of action of current and future MS treatments.
近年来,与多发性硬化症(MS)生物学及治疗相关的文献数量显著增长。本文重点关注人类免疫反应中与MS疾病进程相关的方面,作为必然结果,这些方面也是开发安全有效疗法的合理靶点。关于MS患者免疫病理生理学的许多思考都受到中枢神经系统(CNS)炎症动物模型研究的影响。将这些研究成果转化应用于人类疾病仍面临诸多挑战。本文提出了一个简化的MS免疫病理生理模型,以阐明外周免疫激活以及CNS内局部免疫反应可能影响疾病进程的基本原理,并确定当前及未来MS治疗的假定作用位点。